КАПЛАН Джоанн М. (US),РОБЕРТС Брюс Л. (US),САЙДЕРС Уилльям М. (US)
申请号：
RU2011150495/02
公开号：
RU2011150495A
申请日:
2010.05.13
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of increasing the number of FoxP3 regulatory T cells in a patient with lupus, comprising administering to the patient a therapeutically effective amount of an anti-CD52 antibody. The method of claim 1, further comprising administering to the patient an agent stimulating said regulatory T cells. The method of claim 2, wherein the agent is rapamycin, TGF-β, IL-10, IL-4, IFN-α, vitamin D3, dexamethasone or mycophenolate mofetil. The method according to claim 3, in which TGF-β is an active or latent form of any of TGF-β1, TGF-β2, TGF-β3, TGF-β4 and TGF-β5.5. The method of claim 1, wherein the number of said regulatory T cells is increased in at least one site of inflammation. The method of claim 5, wherein the site of inflammation is blood, central nervous system (CNS), heart, liver, joint, kidney, lungs, skin, intestines, or vascular system. A method for decreasing urine protein, or albumin in urine, or both in a lupus patient, comprising administering to the patient a therapeutically effective amount of an anti-CD52 antibody. The use of anti-CD52 antibodies for the manufacture of a medicament for increasing the number of FoxP3 regulatory T cells in a patient with lupus. 9. The use of claim 8, wherein said patient is administered an agent stimulating said regulatory T cells. The use of anti-CD52 antibodies for the manufacture of a medicament for decreasing the level of protein in the urine, or albumin in the urine, or both in a patient with lupus. 11. The use of claim 10, wherein said patient is administered an agent that stimulates said regulatory T cells. The use of claim 9, wherein said agent is rapamycin, TG1. Способ увеличения количества FoxP3регуляторных T-клеток у пациента с волчанкой, включающий введение пациенту терапевтически эффективного количества анти-CD52 антитела.2. Способ по п.1, дополнительно включающий введение пациенту средства, стимулирующего указанные регуляторные T-клетки.3. Способ по п.2, в котором средство представляет собой рапамици
